Get specific information for US investors on our Novartis US Corporate website.
Syngenta Tax Basis Information
Sales & Reports ›
Novartis has delivered dynamic sales and earnings over the past 10 years. The following information provides more information on the strong financial performance of the company.
US Investor Relations Contacts ›
If you would like investor information, please visit our Novartis US Corporate website for a full list of investor relations contacts.
Share Data and Analysis ›
Learn more about the history and performance of Novartis shares on the NYSE and SWX, ownership details and dividend history.
Investors
Latest News ›
Tasigna® (nilotinib) capsules
June 17, 2010
June 10, 2010
US affiliate of Novartis strongly disputes claims of past discrimination in the US
May 19, 2010
Exforge HCT® (amlodipine, valsartan, hydrochlorothiozide) tablets
May 03, 2010
Tekturna® HCT (aliskiren and hydrochlorothiazide) tablets
May 03, 2010
Zortress® (everolimus) tablets
April 22, 2010
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
ABOUT US
We provide medicines to treat and prevent diseases, ease suffering, and improve quality of life.
OUR PRODUCTS
Novartis is recognized worldwide for bringing to market innovative medicines with improved efficacy and fewer side-effects.
COMPANY HISTORY
Novartis was created in 1996 with the merger of Sandoz and Ciba-Geigy.